X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/zevra-ceo-resigns-as-board-of-directors-sees-change/
https://endpts.com/recursion-acquires-valence-and-cyclica-two-ai-drug-discovery-companies-for-87-5m/
https://www.globenewswire.com/news-release/2023/02/22/2613277/16626/en/CORRECTION-KemPharm-Announces-Corporate-Name-Change-to-Zevra-Therapeutics.html
https://www.globenewswire.com/news-release/2023/01/31/2598307/16626/en/KemPharm-Enhances-Senior-Management-Team.html
https://www.globenewswire.com/news-release/2023/01/24/2594089/16626/en/KemPharm-Issues-Letter-to-Shareholders.html
https://www.globenewswire.com/news-release/2023/01/18/2590811/16626/en/KemPharm-Partners-with-the-Hypersomnia-Foundation-to-Support-Sleep-Disorder-Research-and-Advocacy.html
https://www.globenewswire.com/news-release/2023/01/11/2586936/16626/en/KemPharm-Announces-Promotion-of-Sven-Guenther-Ph-D-to-Chief-Scientific-Officer-and-Christal-Mickle-M-A-to-Chief-Product-Development-Officer.html
https://www.globenewswire.com/news-release/2023/01/09/2584962/16626/en/KemPharm-Announces-Board-and-Leadership-Changes-to-Support-its-Transformation-into-a-Leading-Rare-Disease-Company.html
https://www.globenewswire.com//news-release/2022/12/21/2577785/16626/en/KemPharm-Announces-Initiation-of-Phase-2-Clinical-Trial-Investigating-KP1077-for-the-Treatment-of-Idiopathic-Hypersomnia-IH.html
https://www.globenewswire.com//news-release/2022/11/29/2563896/16626/en/KemPharm-Announces-Appointment-of-Christopher-Posner-as-New-Independent-Director.html
Market Place
Share 
